Clinical Trials · NCT05346848
Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Recruiting
- Sponsor
- Institut Bergonié
- Enrollment
- 62
- Start date
- Feb 2023
- Locations
- 10 sites, France
- Primary endpoint
- Assessment of efficacy in terms of 6-month biological response